Literature DB >> 2422803

Detection of tumor angiogenesis factor in adenocarcinoma of kidney.

R H Bard, J H Mydlo, S Z Freed.   

Abstract

Implantation of human renal adenocarcinoma in the rabbit cornea has resulted in new vascular growth from the limbus toward the tumor implant. This suggests that renal adenocarcinoma elaborates tumor angiogenesis factor (TAF) which stimulates endothelial cell growth. Such a substance could conceivably be responsible for the luxuriant vascularity of most renal adenocarcinomas. Conversely, absence or diminished secretion of TAF may be responsible for the hypovascular papillary renal adenocarcinomas and their recognized relatively benign clinical behavior.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422803     DOI: 10.1016/0090-4295(86)90412-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.

Authors:  A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi
Journal:  Br J Pharmacol       Date:  2016-07-22       Impact factor: 8.739

Review 2.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  Growth factors and renal cancer: characterization and therapeutic implications.

Authors:  J H Mydlo
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 5.  Biology of metastasis and its clinical implications: renal-cell cancer.

Authors:  J C Ulchaker; E A Klein
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.

Authors:  Peter E Clark
Journal:  Biologics       Date:  2010-08-09

Review 7.  The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

Authors:  Peter E Clark
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.